MX2020014102A - Inhibidores de proteina quinasa para promover la regeneracion del higado o reducir o prevenir la muerte de hepatocito. - Google Patents
Inhibidores de proteina quinasa para promover la regeneracion del higado o reducir o prevenir la muerte de hepatocito.Info
- Publication number
- MX2020014102A MX2020014102A MX2020014102A MX2020014102A MX2020014102A MX 2020014102 A MX2020014102 A MX 2020014102A MX 2020014102 A MX2020014102 A MX 2020014102A MX 2020014102 A MX2020014102 A MX 2020014102A MX 2020014102 A MX2020014102 A MX 2020014102A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- protein kinase
- reducing
- liver regeneration
- kinase inhibitors
- Prior art date
Links
- 210000003494 hepatocyte Anatomy 0.000 title abstract 2
- 210000004185 liver Anatomy 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 abstract 3
- 108010068304 MAP Kinase Kinase 4 Proteins 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 abstract 1
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Abstract
La invención se refiere a compuestos de la fórmula (I) que son inhibidores de MKK4 (quinasa 4 de proteína quinasa activada por mitógeno) y su uso para promover la regeneración del hígado o para reducir o prevenir la muerte de hepatocito. Los compuestos inhiben selectivamente la proteína quinasa MKK4 sobre las proteína quinasas JNK y MKK7. (I), en la cual Rx, Ry, Rz y Rzz se seleccionan a partir de: a) Rx y Ry son F y Rz y Rzz son H; b) Rx, Ry y Rzz son de manera independiente halógeno y Rz es H; c) Rx, Rz y Rzz son de manera independiente halógeno y Ry es H; y d) Rx, Ry y Rz son de manera independiente halógeno y Rzz es H.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18183712 | 2018-07-16 | ||
PCT/EP2019/069150 WO2020016243A1 (en) | 2018-07-16 | 2019-07-16 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020014102A true MX2020014102A (es) | 2021-05-27 |
Family
ID=62975936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020014102A MX2020014102A (es) | 2018-07-16 | 2019-07-16 | Inhibidores de proteina quinasa para promover la regeneracion del higado o reducir o prevenir la muerte de hepatocito. |
Country Status (12)
Country | Link |
---|---|
US (1) | US11912701B2 (es) |
EP (1) | EP3823968A1 (es) |
JP (1) | JP7365393B2 (es) |
KR (1) | KR20210035092A (es) |
CN (1) | CN112424201B (es) |
AU (1) | AU2019303986B2 (es) |
BR (1) | BR112020026003A2 (es) |
CA (1) | CA3104246A1 (es) |
IL (1) | IL279641B2 (es) |
MX (1) | MX2020014102A (es) |
SG (1) | SG11202012732UA (es) |
WO (1) | WO2020016243A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020007954A (es) | 2018-01-31 | 2021-01-08 | Heparegenix Gmbh | Inhibidores de la proteina cinasa cinasa 4 activada por mitogeno (mkk4) para promover la regeneracion del higado o reducir o prevenir la muerte de los hepatocitos. |
WO2019243315A1 (en) | 2018-06-21 | 2019-12-26 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CA3104246A1 (en) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CA3137985A1 (en) * | 2019-05-31 | 2020-12-03 | Fochon Pharmaceuticals, Ltd. | Substituted pyrrolo [2, 3-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
CA3164361A1 (en) * | 2020-01-15 | 2021-07-22 | Heparegenix Gmbh | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases |
KR20210135092A (ko) * | 2020-05-04 | 2021-11-12 | 아주대학교산학협력단 | 톨-유사 수용체 7/9 억제 기능이 있는 길항성 소분자 화합물 |
CN111517977B (zh) * | 2020-05-28 | 2023-05-23 | 爱斯特(成都)生物制药股份有限公司 | 一种合成2,4-二氟-3-三甲基乙酰胺基苯甲酸的方法 |
WO2023194443A1 (en) | 2022-04-06 | 2023-10-12 | Heparegenix Gmbh | Pharmaceutical composition for the treatment of colon and lung cancer |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514981B1 (en) | 1998-04-02 | 2003-02-04 | Sugen, Inc. | Methods of modulating tyrosine protein kinase function with indolinone compounds |
CA2464214C (en) | 2001-10-22 | 2011-02-08 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
CA2464934A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
AU2003300522A1 (en) | 2002-12-27 | 2004-07-22 | Bayer Healthcare Ag | 4-phenyl-pyrimido (4,5-b) indole derivatives |
SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
FR2876377B1 (fr) | 2004-10-11 | 2007-03-16 | Univ Claude Bernard Lyon | Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes |
JP2006282745A (ja) | 2005-03-31 | 2006-10-19 | Fuji Photo Film Co Ltd | セルロース誘導体組成物、セルロース誘導体フィルム、および置換安息香酸誘導体化合物 |
EP1885723A2 (en) | 2005-05-17 | 2008-02-13 | Plexxikon, Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
RS52010B (en) | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
CN104601504B (zh) | 2008-07-01 | 2018-12-04 | 爱立信电话股份有限公司 | 在mimo电信系统中使用预编码矩阵的方法和设备 |
EP2161271A1 (en) | 2008-09-08 | 2010-03-10 | Università Degli Studi Di Milano - Bicocca | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl |
EP2406259A1 (en) | 2009-03-11 | 2012-01-18 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
IN2012DN03312A (es) | 2009-10-22 | 2015-10-23 | Fibrotech Therapeutics Pty Ltd | |
CN102753549A (zh) * | 2009-12-23 | 2012-10-24 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
ES2696023T3 (es) | 2011-02-07 | 2019-01-11 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas e indicaciones para ello |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
WO2012135631A1 (en) | 2011-03-30 | 2012-10-04 | Arrien Pharmaeuticals Llc | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
CN107245056A (zh) | 2011-08-26 | 2017-10-13 | 润新生物公司 | 化学实体、组合物及方法 |
TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
RU2015149937A (ru) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | Соединения для модулирования киназы и показания к их применению |
EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ, エルエルシー | 非アルコール性脂肪肝疾患の処置のためのacc阻害剤併用療法 |
WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
KR20200051626A (ko) | 2017-08-07 | 2020-05-13 | 조인트 스탁 컴퍼니 "바이오케드" | Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물 |
MX2020007954A (es) | 2018-01-31 | 2021-01-08 | Heparegenix Gmbh | Inhibidores de la proteina cinasa cinasa 4 activada por mitogeno (mkk4) para promover la regeneracion del higado o reducir o prevenir la muerte de los hepatocitos. |
RU2678455C1 (ru) | 2018-06-01 | 2019-01-29 | Сергей Викторович Леонов | Кристаллическая форма n-(3-(5-(4-хлорофенил)-1н-пиразоло[3,4-в]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамида, активный компонент, фармацевтическая композиция и лекарственное средство |
WO2019243315A1 (en) | 2018-06-21 | 2019-12-26 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CA3104246A1 (en) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
KR20210071976A (ko) | 2018-09-04 | 2021-06-16 | 마젠타 테라퓨틱스 인코포레이티드 | 아릴 하이드로카본 수용체 길항제 및 사용 방법 |
US20220106265A1 (en) | 2018-12-11 | 2022-04-07 | Duke University | Compositions and methods for the treatment of cancer |
US11370770B2 (en) | 2019-06-24 | 2022-06-28 | Northwestern University | 3-arylindazoles as selective MEK4 inhibitors |
CN114269745A (zh) | 2019-07-29 | 2022-04-01 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或减少或预防肝细胞死亡的杂芳基取代的吡唑并吡啶蛋白激酶抑制剂 |
CN112778311A (zh) | 2019-11-01 | 2021-05-11 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
CA3164361A1 (en) | 2020-01-15 | 2021-07-22 | Heparegenix Gmbh | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases |
WO2022150962A1 (en) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
-
2019
- 2019-07-16 CA CA3104246A patent/CA3104246A1/en active Pending
- 2019-07-16 AU AU2019303986A patent/AU2019303986B2/en active Active
- 2019-07-16 US US17/260,519 patent/US11912701B2/en active Active
- 2019-07-16 SG SG11202012732UA patent/SG11202012732UA/en unknown
- 2019-07-16 BR BR112020026003-7A patent/BR112020026003A2/pt unknown
- 2019-07-16 WO PCT/EP2019/069150 patent/WO2020016243A1/en active Application Filing
- 2019-07-16 CN CN201980047654.0A patent/CN112424201B/zh active Active
- 2019-07-16 KR KR1020207036713A patent/KR20210035092A/ko unknown
- 2019-07-16 EP EP19742336.1A patent/EP3823968A1/en active Pending
- 2019-07-16 MX MX2020014102A patent/MX2020014102A/es unknown
- 2019-07-16 IL IL279641A patent/IL279641B2/en unknown
- 2019-07-16 JP JP2021501023A patent/JP7365393B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20210035092A (ko) | 2021-03-31 |
BR112020026003A2 (pt) | 2021-03-23 |
IL279641B2 (en) | 2024-04-01 |
AU2019303986B2 (en) | 2024-02-22 |
IL279641B1 (en) | 2023-12-01 |
JP2021529815A (ja) | 2021-11-04 |
EP3823968A1 (en) | 2021-05-26 |
US20220281864A1 (en) | 2022-09-08 |
WO2020016243A1 (en) | 2020-01-23 |
AU2019303986A1 (en) | 2021-01-14 |
SG11202012732UA (en) | 2021-02-25 |
CN112424201B (zh) | 2024-04-02 |
IL279641A (en) | 2021-03-01 |
CN112424201A (zh) | 2021-02-26 |
US11912701B2 (en) | 2024-02-27 |
JP7365393B2 (ja) | 2023-10-19 |
CA3104246A1 (en) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020014102A (es) | Inhibidores de proteina quinasa para promover la regeneracion del higado o reducir o prevenir la muerte de hepatocito. | |
MX2020007954A (es) | Inhibidores de la proteina cinasa cinasa 4 activada por mitogeno (mkk4) para promover la regeneracion del higado o reducir o prevenir la muerte de los hepatocitos. | |
NZ755835A (en) | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
MX2022001115A (es) | Inhibidores de proteina quinasa de pirazolo-piridina sustituida con heteroarilo para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocito. | |
CR20200376A (es) | Inhibidores de cd73 | |
PH12020551278A1 (en) | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer | |
EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
MX2017013413A (es) | Compuestos de pirazol y metodo para elaborar y usar los compuestos. | |
NZ711376A (en) | Heteroaryl compounds and uses thereof | |
MX2022004937A (es) | Inhibidores de las cinasas raf. | |
MX2018003351A (es) | Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer. | |
PH12014501355A1 (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
EA202090413A1 (ru) | Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы | |
MX2018013191A (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
ATE554087T1 (de) | Neue kinaseinhibitoren | |
AR115871A1 (es) | MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ | |
WO2016085221A3 (ko) | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 | |
MX2018008362A (es) | Derivados de quinolin-2-ona. | |
MX2023003443A (es) | Inhibidores de la proteína cinasa alfa 1 y métodos de uso. | |
CO2022009852A2 (es) | Inhibidores de la proteína leucemia once-diecinueve (enl)/af9 yeats | |
MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
MY201291A (en) | Aminothiazole compounds as protein kinase inhibitors | |
MX2020007521A (es) | Inhibidores de pi4kiii. |